-
1.发明授权Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith 有权二羧酸钙醚，其制备方法，以及治疗血管疾病和糖尿病公开(公告)号：US07141608B2
公开(公告)日：2006-11-28
申请号：US10938203
申请日：2004-09-10
IPC分类号： A01N37/00
CPC分类号： C07C59/305
摘要： Alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt are crystalline and have the formula wherein R1 is H or lower alkyl, and x is a number from 0 to 10, and are useful for treating dyslipidemia.
摘要翻译： 6-（5-羧基-5-甲基 - 己氧基）-2,2-二甲基己酸单钙盐的醇和水溶剂合物是结晶的并且具有下式：其中R 1是H或低级烷基，和 x为0〜10的数，可用于治疗血脂异常。
-
2.发明授权Solid bulk compositions containing quinolone carboxylic acids or naphthyridine carboxylic acids in free base form 失效含有游离碱形式的喹诺酮羧酸或萘啶羧酸的固体本体组合物
公开(公告)号：US5783585A
公开(公告)日：1998-07-21
申请号：US723797
申请日：1996-09-30
IPC分类号： C07D401/04 , A61K31/47 , A61P31/04 , C07D215/56 , C07D471/04 , A61K31/435
CPC分类号： C07D215/56 , C07D471/04
摘要： The present invention provides a method of making quinolone carboxylic acids or naphthyridine carboxylic acids in free base form, the method comprising dissolving a quinolone carboxylic acid salt or naphthyridine carboxylic acid salt in a solvent system to form a solution; combining the solution containing the quinolone carboxylic acid salt or naphthyridine carboxylic acid salt with a calcium salt in an amount in the range of about 0.01% to about 5.0% by weight of the quinolone carboxylic acid salt or naphthyridine carboxylic acid salt and a base, the combination resulting in the formation of a precipitate; and collecting the precipitate. Also provided is a solid bulk pharmaceutical chemical composition comprising 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid or 7-�3-S-(2-S-aminopropionylamino)pyrrolidin-1-yl!-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; and calcium in an amount in the range of 0.001% to about 1.0% by weight of the 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid or 7-�3-S-(2-S-aminopropionylamino) pyrrolidin-1-yl!-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
摘要翻译： 本发明提供以游离碱形式制备喹诺酮羧酸或萘啶羧酸的方法，所述方法包括将喹诺酮羧酸盐或萘啶羧酸盐溶解在溶剂体系中以形成溶液; 将含有喹诺酮羧酸盐或萘啶羧酸盐的溶液与喹啉酮羧酸盐或萘啶羧酸盐和碱的重量比为约0.01％至约5.0％的钙盐组合， 组合导致沉淀物的形成; 并收集沉淀物。 还提供了包含7-（3-氨基-1-吡咯烷基）-8-氯-1-环丙基-6-氟-1,4-二氢-4-氧代喹啉-3-羧酸或7 - [3-S-（2-S-氨基丙酰基氨基）吡咯烷-1-基] -1-环丙基-6-氟-1,4-二氢-4-氧代-1,8-二氮杂萘-3-羧酸; 和以重量计为0.001％至约1.0％的量的7-（3-氨基-1-吡咯烷基）-8-氯-1-环丙基-6-氟-1,4-二氢-4 - 氧代喹啉-3-羧酸或7- [3-S-（2-S-氨基丙酰基氨基）吡咯烷-1-基] -1-环丙基-6-氟-1,4-二氢-4-氧代-1,8 - 萘啶-3-羧酸。
-
3.发明授权Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith 有权二羧酸钙醚，其制备方法，以及治疗血管疾病和糖尿病公开(公告)号：US06861555B2
公开(公告)日：2005-03-01
申请号：US10018617
申请日：2001-01-11
IPC分类号： C07C59/305 , C07C229/00 , A01N37/00
CPC分类号： C07C59/305
摘要： Alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt are crystalline and have the formula (I), wherein R1 is H or lower alkyl, and x is a number from 0 to 10, and are useful for treating dyslipidemia.
摘要翻译： 6-（5-羧基-5-甲基 - 己氧基）-2,2-二甲基己酸单钙盐的醇和水溶剂化物是结晶的，具有式（I），其中R 1是H或低级烷基，x是数 从0至10，并且可用于治疗血脂异常。
-
-
搜索结果
3 条记录 (耗时 0.017 秒)
